Prometic Life Sciences will present new data on the benefits of plasminogen administration to reduce lung injury in animal model associated with acute pancreatitis.
Prometic Life Sciences (TSX:PLI) (OTCQX:PFSCF) will be showing new data on the benefits of plasminogen administration in order to reduce lung injury in animal model associated with acute pancreatitis at the upcoming American thoracic Society conference.
As quoted in the press release:
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are life-threatening conditions resulting in respiratory failure in the critically ill patient. ALI is the term used to describe the pulmonary response to a broad range of injuries occurring either directly to the lung or as a consequence of injury or inflammation at other sites of the body, such as acute pancreatitis, severe burns, trauma, or sepsis. ARDS represents the more severe subset of this condition. ALI and ARDS affect approximately 190,000 patients every year in the US, and are associated with a high mortality rate varying between 30% and 60%; both conditions representing significant unmet medical needs.
“ALI and ARDS are just two examples of acute critical care conditions we intend to pursue with our plasminogen product once it receives regulatory approval for congenital deficiency”, stated Dr. John Moran, Prometic’s Chief Medical Officer. “The remarkable results seen with plasminogen in this gold standard model for ALI/ARDS strongly suggests its potential to address these major unmet medical needs.”